Hematology-Oncology
Latest news
316 articles · 20 / page
Breaking the Cystine Barrier: Long-term Safety and Efficacy of CTNS-RD-04 Gene Therapy in Cystinosis
A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.
Europe’s Hidden Hyperinflammatory Crisis: HLH Mortality Rates Nearly Double Over a Decade
A retrospective study across 29 European countries reveals that mortality from haemophagocytic lymphohistiocytosis (HLH) increased significantly between 2011 and 2021, with notable bimodal age peaks and geographical disparities suggesting w
Cilta-cel Redefines Survival in Lenalidomide-Refractory Multiple Myeloma: Long-term Results from CARTITUDE-4
The updated CARTITUDE-4 analysis demonstrates that cilta-cel significantly improves overall survival and progression-free survival compared to standard therapies in lenalidomide-refractory multiple myeloma patients after the first relapse,
Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia
A Phase 1 study demonstrates that iTAC-XS15-CLL01, a personalised multipeptide T-cell activator, induces robust immune responses in 95% of CLL patients on BTK inhibitors, offering a potential path to sustainable cancer control and eradicati
Standard Preventive Interventions for Vasovagal Reactions Fail to Show Benefit in Massive 1.4 Million Donor Trial
The STRIDES trial, the largest of its kind, demonstrates that isotonic drinks, extended rest, modified muscle tension, and psychosocial support do not significantly reduce vasovagal reactions in blood donors compared to existing UK standard
Cabozantinib Plus Temozolomide: A Promising Dual-Pathway Approach for Advanced Leiomyosarcoma
A phase 2 trial demonstrates that combining cabozantinib with temozolomide provides significant progression-free survival benefits for patients with advanced leiomyosarcoma, achieving a 74% 12-week PFS rate with a manageable safety profile,
Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials
A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap i
Resminostat Maintenance Therapy Significantly Delays Disease Progression in Advanced Cutaneous T-Cell Lymphoma
The RESMAIN trial demonstrates that resminostat maintenance therapy doubles median progression-free survival in patients with advanced mycosis fungoides or Sézary syndrome, offering a potential new standard for managing patients who have ac
CPX-351 Benefit in AML is Driven by Myelodysplasia-Related Mutations: Insights from a Phase 3 Molecular Re-analysis
A molecular re-evaluation of the pivotal CPX-351 phase 3 trial reveals that its survival benefit is selectively confined to patients with myelodysplasia-related mutations (AML-MR), with no significant advantage over standard 7+3 induction i
Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL
The CART19-BE-02 phase 2 trial demonstrates that varnimcabtagene autoleucel, utilizing a unique fractionated dose escalation strategy, achieves an 84.4% MRD-negative complete response rate in adults with relapsed or refractory B-ALL while s
Beyond Standard Staging: A Novel Genetics-Based Model Refines Prognosis for AML Patients Treated with Venetoclax and Hypomethylating Agents
A newly developed prognostic model integrates mutational and cytogenetic data to accurately predict survival in AML patients receiving HMA/VEN therapy, offering superior risk stratification into low-, intermediate-, and high-risk categories
Beyond the Count: How Product Factors and High Thresholds Shape Pediatric Platelet Transfusion Outcomes
A multicenter cohort study of 8,874 pediatric patients reveals that most prophylactic platelet transfusions occur above recommended thresholds. Factors such as pathogen reduction, additive solutions, and donor age significantly lower posttr
Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis
A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer al
Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial
The RJBC 1501 Phase III trial demonstrates that adding carboplatin to adjuvant EC-T chemotherapy significantly improves disease-free, distant disease-free, and overall survival in early-stage TNBC patients, despite a manageable increase in
Venetoclax-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: A Critical Appraisal of the Phase III CANOVA Study
The Phase III CANOVA trial evaluated venetoclax-dexamethasone against pomalidomide-dexamethasone in t(11;14)-positive RRMM. While the primary endpoint of progression-free survival was not statistically met, the study revealed significant im
Beyond the CNS and Skeleton: HSPC-Gene Therapy (OTL-203) Demonstrates Superior Multi-System Efficacy in Hurler Syndrome
A clinical study comparing OTL-203 gene therapy to allogeneic HSCT for Hurler syndrome reveals significant improvements in corneal clarity, hearing preservation, and cardiac stability, marking a potential shift in the standard of care for m
Rogocekib Demonstrates Clinical Activity as a First-in-Class CLK Inhibitor in Relapsed or Refractory AML and MDS
This Phase 1 study evaluates rogocekib, a novel CDC2-like kinase inhibitor, in patients with relapsed or refractory hematologic malignancies, reporting manageable safety and significant complete remission rates in AML and MDS cohorts, signa
Iptacopan: A Comprehensive Clinical Review of the First-in-Class Oral Factor B Inhibitor for PNH and Complement-Mediated Nephropathies
This review synthesizes clinical trial evidence for Iptacopan, focusing on its transformative role in treating PNH through proximal complement inhibition and its emerging efficacy in IgA nephropathy and C3 glomerulopathy.
Iptacopan Demonstrates Clinical Efficacy in Cold Agglutinin Disease While Falling Short in Immune Thrombocytopenia: Results from a Phase 2 Basket Trial
This Phase 2 basket trial highlights the divergent efficacy of the oral factor B inhibitor iptacopan, showing significant hemoglobin improvements in Cold Agglutinin Disease but failing to meet platelet response endpoints in Immune Thrombocy
Colchicine May Curb the Expansion of Pro-Inflammatory Clonal Hematopoiesis: Insights From the LoDoCo2 Substudy
A substudy of the LoDoCo2 trial suggests that low-dose colchicine may attenuate the expansion of specific clonal hematopoiesis driver mutations, particularly TET2, offering a potential mechanism for reducing cardiovascular risk by slowing t
Browse by specialty
Open language-specific specialty feeds and department pages.